How to Prostate cancer?

Patents

Literature

Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.

Hiro

6 results about "Prostate cancer" patented technology

Filter

Efficacy Topic

Property

Owner

Technical Advancement

Application Domain

Technology Topic

Technology Field Word

Patent Country/Region

Patent Type

Patent Status

Application Year

Inventor

A cancer of the prostate gland, a part of the male reproductive system.

Thioredoxin reductase inhibiter compounds and preparation method and application thereof

ActiveCN101781283AOrganic chemistryAntineoplastic agentsMelanomaProstate cancer

The invention discloses thioredoxin reductase inhibiter compounds, which have antitumor activity, particularly have growth inhibition activity for solid tumor, wherein the solid tumor is thyroid cancer, prostatic cancer, colon cancer, rectal cancer, melanoma, liver cancer, lung cancer, gastric cancer, carcinoma submaxilary gland, nasopharyngeal darcinoma or breast cancer.

Owner:KEAISE MEDICINE WUHAN

Prostate Cancer Biomarkers

ActiveUS20170010269A1Easy to manageConvenient treatmentDisease diagnosisEnzymesProstate cancerOncology

A method is provided for characterising and / or prognosing prostate cancer in a subject comprising measuring the level of at least one protein from a panel or at least one peptide thereof in a sample from the subject. The method may be used to determine the grade and stage of the prostate cancer. Also disclosed is a method for selecting a treatment for prostate cancer, together with corresponding methods of treatment. Systems and computing devices for performing the methods are also provided.

Owner:UNIV COLLEGE DUBLIN NAT UNIV OF IRELAND DUBLIN

Nano-vesicles derived from genus cupriavidus bacteria and use thereof

InactiveUS20190390284A1Inhibition of secretionNervous disorderNanomedicineProstate cancerObstructive Pulmonary Diseases

Provided are vesicles derived from bacteria belonging to the genus Cupriavidus, a composition and a use thereof, wherein the vesicles or composition may be usefully used for the purpose of developing a method of diagnosing a malignant diseases such as gastric cancer, colon cancer, pancreatic cancer, cholangiocarcinoma, breast cancer, ovarian cancer, bladder cancer, prostate cancer, head and neck cancer, lymphoma, and the like, heart diseases such as cardiomyopathy, atrial fibrillation, variant angina, and the like, chronic obstructive pulmonary disease, stroke, diabetes, kidney failure, dementia, Parkinson's disease, or depression.

Owner:MD HEALTHCARE INC

Method for preparing apalutamide intermediate as drug for treating prostate cancer through catalysis

ActiveCN108311155AOvercome the shortcomings of not suitable for large-scale production and large environmental pollutionHigh selectivityOrganic chemistryCatalyst activation/preparationProstate cancerHydrotalcite

The invention belongs to the technical field of medicine, and particularly relates to a method for preparing an apalutamide intermediate as a drug for treating prostate cancer through catalysis. According to the method, Ce(NO3)3.6H2O and Ni(NO3)2.6H2O serve as a Ce source and a Ni source to prepare a Ni/Ce compound metal oxide, Mg(NO3)2.6H2O and Al(NO3)2.9H2O serve as a magnesium source and an aluminum source to prepare magnalium aluminum hydrotalcite, and the Ni/Ce compound metal oxide, which serves an active ingredient, is in situ loaded onto a surface of the magnalium aluminum hydrotalciteand/or into a layered cavity when a coprecipitation method is used for preparing the magnalium aluminum hydrotalcite. The prepared Ni/Ce compound metal oxide loaded on the hydrotalcite can be used forcatalyzing 2-cyano-3-trifluoromethyl-5-nitropyridine to generate the apalutamide intermediate 2-cyano-3-trifluoromethyl-5-aminopyridine as the drug for treating the prostate cancer. The catalytic system of the invention is high in yield, and the target product is good in selectivity.

Method for preparing apalutamide intermediate as drug for treating prostate cancer through catalysis

View all

Owner:上海奥萝拉医药科技有限公司

Pta089 protein

InactiveUS20120058131A1Avoid developmentSymptoms improvedMicrobiological testing/measurementDepsipeptidesProstate cancerOncology

The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of bladder cancer, colorectal cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, prostate cancer or skin cancer, for monitoring the effectiveness of bladder cancer, colorectal cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, prostate cancer or skin cancer treatment, and for drug development.

Owner:OXFORD BIOTHERAPEUTICS